FDA Considers Cuts And Initiatives For Fiscal 2014 – Hamburg
This article was originally published in The Tan Sheet
Commissioner Hamburg tells FDA’s Science Board that in the early stages, both cuts and expansions are on the table as the budget process begins in preparation for the fiscal year starting October 2013.
You may also be interested in...
Congress sets $52.9 million floor for Office of Generic Drugs in FY 2012, less than in 2011, as part of $3.8 billion FDA funding package. Overall, FDA gets a $50 million boost, but sequestration looms. Appropriations conferees enter the user fee debate, asking how fast FDA approves drug applications.
Grail Sipes, CDER deputy center director for regulatory policy, will move to the Executive Office of the President next month.
After more review of clinical trial data, the myeloma drug’s sponsor wants to talk to the FDA again, but Oncopeptides execs said they cannot disclose the scientific details that led to the decision.